Acetyl-TUBA1A/TUBA1B/TUBA1C (K112) Antibody

What is the Acetyl-TUBA1A/TUBA1B/TUBA1C (K112) Antibody and what epitope does it specifically recognize?

The Acetyl-TUBA1A/TUBA1B/TUBA1C (K112) Antibody is a polyclonal antibody produced in rabbits that specifically recognizes the acetylated lysine residue at position 112 (acLys112) of alpha-tubulin isotypes TUBA1A, TUBA1B, and TUBA1C. This antibody is generated using a synthesized peptide derived from human tubulin alpha around the acetylation site of K112 as the immunogen. The antibody is typically affinity-purified from rabbit antiserum using epitope-specific immunogen chromatography to ensure high specificity .

What experimental applications is the Acetyl-TUBA1A/TUBA1B/TUBA1C (K112) Antibody validated for?

This antibody has been validated primarily for Western Blotting (WB) and ELISA applications in research settings. For optimal results, the recommended dilutions are:

These applications allow researchers to detect and quantify acetylated tubulin at K112 in various experimental contexts, particularly when examining neuronal development and microtubule dynamics .

What species cross-reactivity has been confirmed for this antibody?

The antibody has confirmed cross-reactivity with human, mouse, and rat samples, making it suitable for comparative studies across these mammalian models. This multi-species reactivity is particularly valuable for translational research examining evolutionary conservation of tubulin acetylation mechanisms .

How should researchers optimize Western blot protocols when using the Acetyl-TUBA1A/TUBA1B/TUBA1C (K112) Antibody?

When optimizing Western blot protocols with this antibody, researchers should consider several methodological approaches:

• Sample preparation: Extract proteins using buffers containing deacetylase inhibitors (e.g., TSA at 1μM) to preserve acetylation status.

• Loading controls: Include total α-tubulin detection in parallel to assess the ratio of acetylated to total tubulin.

• Blocking: Use 5% BSA rather than milk to reduce background, as milk contains bioactive compounds that may affect results.

• Antibody incubation: Start with a 1:1000 dilution in TBS-T with 1% BSA and incubate overnight at 4°C for optimal signal-to-noise ratio.

• Validation: Include positive controls (e.g., samples treated with HDAC inhibitors) and negative controls (e.g., samples treated with deacetylases).

This methodological approach ensures reliable detection of acetylated tubulin at K112 while minimizing non-specific binding and background signals .

How can researchers effectively use this antibody to study microtubule dynamics in neuronal development?

To effectively study microtubule dynamics in neuronal development using this antibody:

• Establish baseline acetylation levels in control neurons at different developmental stages.

• Combine immunofluorescence with time-lapse imaging to correlate acetylation status with microtubule stability and neuronal morphogenesis.

• Use dual labeling with tyrosinated tubulin antibodies to distinguish between stable (acetylated) and dynamic (tyrosinated) microtubule populations.

• Assess changes in K112 acetylation patterns during critical developmental processes such as axon specification, neurite branching, and growth cone navigation.

• Apply pharmacological agents (HDAC inhibitors or activators) to modulate acetylation levels and observe the effects on neuronal morphology and function.

This approach has revealed that tubulin acetylation status, including at K112, correlates with microtubule stability and influences neurite branching and axon development. In neurons expressing wild-type TUBA1A, acetylated tubulin localizes primarily to the axon while tyrosinated tubulin distributes throughout the neuron .

What are the optimal storage and handling conditions for maintaining antibody performance?

To maintain optimal antibody performance:

• Store the antibody at -20°C or -80°C in aliquots to minimize freeze-thaw cycles.

• Avoid repeated freezing and thawing, which can lead to antibody degradation and reduced activity.

• When preparing working dilutions, use fresh buffer solutions containing 0.02% sodium azide as a preservative.

• For long-term storage solutions, the antibody is typically supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide.

• Handle sodium azide-containing solutions with appropriate safety precautions as it is a hazardous substance.

Proper storage and handling significantly impact experimental reproducibility and the longevity of antibody reagents .

How can Acetyl-TUBA1A/TUBA1B/TUBA1C (K112) Antibody be used to investigate tubulinopathies associated with TUBA1A mutations?

Investigating tubulinopathies with this antibody requires a multifaceted approach:

• Generate cellular models expressing TUBA1A mutants identified in patients with tubulinopathies.

• Use the antibody to assess whether mutations affect the acetylation status at K112.

• Correlate acetylation levels with microtubule polymerization rates and stability.

• Implement dual immunolabeling to examine the relationship between K112 acetylation and recruitment of microtubule-associated proteins (MAPs).

• Compare results across mutation severity spectrum to establish genotype-phenotype correlations.

Research has shown that TUBA1A mutations (such as V409I/A) can disrupt neuronal migration and promote excessive neurite branching, accompanied by increased microtubule acetylation and polymerization rates. The severity of molecular phenotypes often correlates with the severity of clinical manifestations in patients .

What approaches should be used to distinguish between the contributions of different tubulin isotypes (TUBA1A, TUBA1B, TUBA1C) when using this antibody?

To distinguish between tubulin isotypes while using this pan-isotype acetylation antibody:

• Implement complementary techniques like isotype-specific RT-qPCR to quantify relative expression levels of each isotype in the experimental system.

• Utilize genetic manipulation approaches (siRNA, CRISPR-Cas9) to selectively deplete individual isotypes and assess the impact on K112 acetylation signal.

• Employ mass spectrometry to quantify isotype-specific peptides containing acetylated K112.

• Consider developmental timing and tissue specificity - TUBA1A constitutes over 95% of α-tubulin in the embryonic brain and remains a significant component in adult neurons.

• Use novel tubulin tagging methods that don't impair tubulin function to specifically track individual isotypes.

This integrated approach helps deconvolute the contribution of each isotype to the observed acetylation pattern. Research indicates that TUBA1A is the predominant isotype in neuronal contexts, providing over 95% of α-tubulin in the embryonic brain .

How can researchers interpret conflicting data between acetylation levels and microtubule stability in experimental models?

When confronting contradictory results between acetylation levels and microtubule stability:

• Consider multiple markers of microtubule stability beyond acetylation, including detyrosination and polyglutamylation.

• Assess temporal dynamics - acetylation may precede or follow changes in stability depending on the cellular context.

• Evaluate the impact of microtubule-associated proteins that might influence both acetylation and stability independently.

• Examine drug treatments systematically - some compounds may have off-target effects beyond their impact on acetylation.

• Implement live-cell imaging with fluorescently tagged tubulin to directly observe microtubule dynamics alongside fixed-cell analysis of acetylation patterns.

Studies have shown that while acetylation often correlates with microtubule stability, the relationship is not always direct. For instance, certain TUBA1A mutations associated with tubulinopathies exhibit increased acetylation alongside faster polymerization rates, challenging simplistic models of acetylation's role in microtubule dynamics .

What controls should be included when validating experimental results using this antibody?

Comprehensive validation requires multiple controls:

These controls collectively ensure that observed signals genuinely represent K112 acetylation and allow for accurate quantification and interpretation of results .

How can researchers address weak or inconsistent signals when using Acetyl-TUBA1A/TUBA1B/TUBA1C (K112) Antibody?

To troubleshoot weak or inconsistent signals:

• Preserve acetylation during sample preparation by incorporating HDAC inhibitors in lysis buffers.

• Optimize antibody concentration - try a dilution series (1:500, 1:1000, 1:2000) to determine optimal signal-to-noise ratio.

• Extend primary antibody incubation time to overnight at 4°C to enhance signal without increasing background.

• Consider antigen retrieval methods for fixed tissue samples to improve epitope accessibility.

• Verify protein transfer efficiency in Western blots using reversible staining methods.

• Increase exposure time during imaging while ensuring you remain in the linear detection range.

Inconsistent signals often result from variations in acetylation states under different experimental conditions or incomplete preservation of post-translational modifications during sample processing .

How does K112 acetylation of tubulin relate to other post-translational modifications in microtubule regulation?

K112 acetylation represents one element in a complex "tubulin code" of post-translational modifications:

• Relationship with other modifications: K112 acetylation may work synergistically or antagonistically with other modifications like detyrosination, polyglutamylation, and phosphorylation.

• Hierarchical organization: Research suggests certain modifications may precede others, creating a sequential pattern of tubulin regulation.

• Spatial distribution: K112 acetylation shows distinct localization patterns in neurons, being primarily concentrated in axons, while tyrosinated tubulin appears throughout the neuron.

• Functional interplay: The combination of modifications collectively determines microtubule stability, protein interaction profiles, and susceptibility to severing enzymes.

• Temporal dynamics: The pattern of modifications changes during neuronal development, with distinct profiles at different developmental stages.

Studies of TUBA1A mutants reveal that alterations in acetylation patterns correlate with abnormal neuronal morphogenesis and migration, suggesting critical roles for proper regulation of this modification in neurodevelopment .

What are the methodological approaches for studying the impact of K112 acetylation on microtubule-associated protein interactions?

To study how K112 acetylation affects interactions with microtubule-associated proteins:

• Proximity ligation assays (PLA) to detect in situ interactions between acetylated tubulin and binding partners.

• Differential co-immunoprecipitation using the Acetyl-TUBA1A/TUBA1B/TUBA1C (K112) Antibody compared to pan-tubulin antibodies.

• Peptide pull-down experiments comparing acetylated and non-acetylated K112-containing peptides to identify differential binding partners.

• Super-resolution microscopy to visualize co-localization patterns at nanoscale resolution.

• In vitro reconstitution experiments with purified components to directly assess binding kinetics and affinities.

Research has shown that tubulin mutations, which may affect acetylation patterns, can disrupt interactions with microtubule regulators like XMAP215/Stu2 and affect TOG domain binding. These disruptions may contribute to the pathological mechanisms in tubulinopathies .

How can researchers effectively study the relationship between tubulin K112 acetylation and neuronal function in disease models?

To investigate the relationship between K112 acetylation and neuronal pathology:

• Generate patient-derived iPSCs from individuals with tubulinopathies and differentiate them into neurons.

• Compare K112 acetylation patterns between patient and control neurons using the antibody in combination with neuronal markers.

• Implement live-cell imaging to correlate acetylation status with electrophysiological properties and axonal transport dynamics.

• Develop animal models expressing tubulinopathy-associated mutations and assess behavioral outcomes alongside molecular analyses.

• Apply acetylation modulators (HDAC inhibitors/activators) to determine if normalizing acetylation patterns can rescue pathological phenotypes.

Research has demonstrated that TUBA1A mutations can lead to altered microtubule acetylation patterns, which correlate with impaired neuronal migration, abnormal axon guidance, and synaptogenesis defects. These cellular phenotypes potentially underlie the brain malformations observed in tubulinopathy patients .